Stock Scorecard
Stock Summary for Mimedx Group Inc (MDXG) - $6.77 as of 10/24/2025 5:46:47 PM EST
Total Score
13 out of 30
Safety Score
37 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for MDXG
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for MDXG
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for MDXG
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for MDXG
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for MDXG (37 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 3 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 5 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for MDXG
Financial Details for MDXG
Company Overview |
|
|---|---|
| Ticker | MDXG |
| Company Name | Mimedx Group Inc |
| Country | USA |
| Description | MiMedx Group, Inc. (MDXG) is a leading regenerative medicine company headquartered in Marietta, Georgia, specializing in the development and distribution of cutting-edge placental tissue allografts. These innovative products play a vital role in both wound care and surgical applications, significantly enhancing healing processes and improving patient outcomes. Leveraging proprietary technologies and a strong research foundation, MiMedx is strategically positioned to meet the dynamic needs of healthcare providers, while driving advancements in the regenerative medicine sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 10/29/2025 |
Stock Price History |
|
| Last Day Price | 6.77 |
| Price 4 Years Ago | 6.04 |
| Last Day Price Updated | 10/24/2025 5:46:47 PM EST |
| Last Day Volume | 429,413 |
| Average Daily Volume | 637,297 |
| 52-Week High | 10.14 |
| 52-Week Low | 5.64 |
| Last Price to 52 Week Low | 20.04% |
Valuation Measures |
|
| Trailing PE | 32.10 |
| Industry PE | 22.95 |
| Sector PE | 41.12 |
| 5-Year Average PE | 11.34 |
| Free Cash Flow Ratio | 8.46 |
| Industry Free Cash Flow Ratio | 14.54 |
| Sector Free Cash Flow Ratio | 31.25 |
| Current Ratio Most Recent Quarter | 4.39 |
| Total Cash Per Share | 0.80 |
| Book Value Per Share Most Recent Quarter | 1.46 |
| Price to Book Ratio | 4.58 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.29 |
| Price to Sales Ratio Twelve Trailing Months | 2.74 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.95 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.43 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 147,959,000 |
| Market Capitalization | 1,001,682,430 |
| Institutional Ownership | 70.94% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -49.80% |
| Annual Earnings Growth | -37.10% |
| Reported EPS 12 Trailing Months | 0.21 |
| Reported EPS Past Year | 0.15 |
| Reported EPS Prior Year | 0.31 |
| Net Income Twelve Trailing Months | 32,174,000 |
| Net Income Past Year | 42,419,000 |
| Net Income Prior Year | 67,439,000 |
| Quarterly Revenue Growth YOY | 13.10% |
| 5-Year Revenue Growth | -0.58% |
| Operating Margin Twelve Trailing Months | 12.60% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 118,869,000 |
| Total Cash Past Year | 104,416,000 |
| Total Cash Prior Year | 82,000,000 |
| Net Cash Position Most Recent Quarter | 101,658,000 |
| Net Cash Position Past Year | 86,586,000 |
| Long Term Debt Past Year | 17,830,000 |
| Long Term Debt Prior Year | 48,099,000 |
| Total Debt Most Recent Quarter | 17,211,000 |
| Equity to Debt Ratio Past Year | 0.92 |
| Equity to Debt Ratio Most Recent Quarter | 0.93 |
| Total Stockholder Equity Past Year | 193,107,000 |
| Total Stockholder Equity Prior Year | 142,717,000 |
| Total Stockholder Equity Most Recent Quarter | 216,624,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 55,968,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 0.38 |
| Free Cash Flow Past Year | 64,515,000 |
| Free Cash Flow Prior Year | 24,788,000 |
Options |
|
| Put/Call Ratio | 1.16 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.10 |
| MACD Signal | -0.07 |
| 20-Day Bollinger Lower Band | 5.89 |
| 20-Day Bollinger Middle Band | 6.75 |
| 20-Day Bollinger Upper Band | 7.60 |
| Beta | 1.73 |
| RSI | 45.78 |
| 50-Day SMA | 7.53 |
| 150-Day SMA | 6.73 |
| 200-Day SMA | 6.04 |
System |
|
| Modified | 10/23/2025 4:17:39 AM EST |